We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hemogenyx Pharmaceuticals Plc | LSE:HEMO | London | Ordinary Share | GB00BYX3WZ24 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0025 | -0.14% | 1.76 | 1.73 | 1.76 | 1.75 | 1.73 | 1.74 | 7,822,292 | 16:35:08 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.98M | -0.0035 | -4.97 | 19.87M |
TIDMHEMO
RNS Number : 5017W
Hemogenyx Pharmaceuticals PLC
15 November 2017
Hemogenyx Pharmaceuticals Plc
("Hemogenyx" or the "Company")
Directorate change
Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, announces that following the successful completion of the Company's readmission and trading on the main market of the London Stock Exchange, Timothy Le Druillenec, Finance Director, has advised the Board of his intention to step down as a Director at the end of the month and will not be seeking re-election at the forthcoming annual general meeting of the Company in order to pursue other interests.
Timothy was previously Chief Financial Officer of Silver Falcon plc and the Board is in process of putting in place appropriate arrangements for the future financial management of the Company.
Dr Robin Campbell, Chairman of Hemogenyx, commented: "I would like to thank Timothy for his contribution to the Company, and in particular his support during the successful acquisition of Hemogenyx and our listing on the London Stock Exchange."
Enquiries:
Hemogenyx Pharmaceuticals Limited www.hemogenyx.com Dr Vladislav Sandler, Chief Via Walbrook PR Executive Officer & Co-Founder Dr Robin Campbell, Chairman Optiva Securities Ltd Tel: +44 (0)20 3137 1902 Christian Dennis Shard Capital Partners LLP Tel: +44 (0)20 7186 9950 Damon Heath, Erik Woolgar Peterhouse Corporate Finance Tel: +44 (0)20 7469 0930 Limited Lucy Williams/Duncan Vasey Walbrook PR Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com Paul McManus Mob: +44 (0)7980 541 893
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, Hemogenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York. Hemogenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. Hemogenyx's two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care. For more information, visit www.hemogenyx.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAGGGBUGUPMGMC
(END) Dow Jones Newswires
November 15, 2017 02:01 ET (07:01 GMT)
1 Year Hemogenyx Pharmaceuticals Chart |
1 Month Hemogenyx Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions